← Back to Search
Anti-cancer drug
A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Fairway, KS
Phase 1 & 2
Waitlist Available
Led By Jeffrey Lancet, MD
Research Sponsored by Prescient Therapeutics, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.
See full description
Eligible Conditions
- Acute Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Treatment-related Adverse Events
Secondary study objectives
Phospho-Akt (pAkt) expression within CD34+ leukemic blasts
Awards & Highlights
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: PTX-200 and cytarabineExperimental Treatment2 Interventions
PTX-200 administered intravenously over 1 hour
Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed.
Phase II: maximum tolerated dose. given as a 1 hour infusion
Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PTX-200
2016
Completed Phase 2
~40
Cytarabine
FDA approved
Find a Location
Closest Location:University of Kansas Cancer Center· Fairway, KS
Who is running the clinical trial?
Prescient Therapeutics, Ltd.Lead Sponsor
6 Previous Clinical Trials
227 Total Patients Enrolled
Jeffrey Lancet, MDPrincipal InvestigatorMoffitt Cancer Center